Sustainability

Imposing extended producer responsibility (EPR) laws on medical device makers would be an excessive regulation given that most major companies in the industry have already implemented voluntary programs for free consumer battery recycling.

Rather than create a patchwork of statutes across jurisdictions, lawmakers should allow the comprehensive standards established by national microplastics and microbead legislation to facilitate steady industry progress on materials and waste reduction guided by science.

Imposing Proposition 65 state-level requirements on chemicals actively regulated under federal purview risks duplicative warnings that undermine public trust in national safety determinations. Since the FDA derives allowable limits from the best available science, overriding federal risk-benefit guidelines with California-specific thresholds triggers unnecessary labeling not reflecting real-world exposures from routine product usage shown to be safe.

While a small select group have raised concerns about certain sunscreen ingredients, banning or restricting common UV filters could negatively impact public health.

Rather than legislate additional state-level extended producer responsibility mandates aimed at packaging, lawmakers should support manufacturers already innovating sustainability solutions within the FDA's extensive regulatory framework that balances both environmental considerations and patient safety needs.

Lawmakers should support the centralized progress made on ingredient evaluation, labeling, and packaging protections by specialized national children’s health agencies instead of allowing jurisdiction confusion that ultimately hinders healthcare advancement for all ages.

View members-only reports outlining progress on CHPA state legislative priorities.

CHPA opposes mandatory manufacturer-funded drug take-back programs as they threaten the affordability of OTC medications that consumers rely on as the first line of defense against common ailments.

CHPA encourages state and local lawmakers to refrain from creating new legislation addressing green chemistry in pharmaceuticals, and instead rely on the rigorous guidelines and standards already implemented at the federal level by agencies like the FDA.

Though rising PFAS levels prompt important health questions that must be monitored, restrictions should remain grounded in conclusive toxicology to avoid reactionary bans on safe modern alternatives — as inconsistent standards across 50 individual states would only stifle healthcare advancement.